DIMERx
Company Details
Status: Private
Employees: 1-10
Location:
San Francisco, California, United States
Type:
sample
Technology:
sample
sample
sample
About: DIMERx is a clinical-stage biopharmaceutical company pioneering a proprietary dimer technology platform to develop novel chemical entities for high-impact, underserved medical conditions. Co-founded by Gregory Beyer, Harvinder Dhani, and Nikhilesh Singh, PhD, the company also collaborates closely on clinical strategy with Maurizio Fava, MD, Chair, Mass General Brigham Academic Medical Centers Psychiatry Department.
The company’s lead asset, DMX-101, is a covalently modified, chemically stable, halogen-free buprenorphine dimer (CAS No: 1820753-68-1) that acts peripherally at the source to provide non-addictive pain relief. DMX-101 is in phase 2 clinical development for chronic lower back pain. Across Phase 1 and Phase 2a studies involving over 400 human subjects and patients, it has demonstrated a favorable safety profile—including pancreatic safety—and clear analgesic benefits.
DIMERx’s second program, DMX-201, is a covalently linked dimer of arginine and agmatine—a next-generation nitric oxide (NO) donor being developed for conditions involving endothelial dysfunction, such as vaso-occlusive crisis (VOC) pain in sickle cell disease, where treatment options remain dominated by centrally acting opioids.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
DIMERx | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.